Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation.

Abstract

There is no established standard treatment for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in patients who are not eligible to receive an intensive treatment. The combination of rituximab gemcitabine and oxaliplatin (R-GemOx) is widely used in this population but data are scarce. We retrospectively collected the data of 196 patients with R/R DLBCL treated with R-GemOx in two French centers over a period of 15 years. The median age of the population was 72 years (range, 24-89), 63% of the patients had an international prognostic index of 3 or higher and 57% were refractory to the last treatment. At the end of R-GemOx treatment, 33% of the patients obtained a complete response. The median progression-free survival (PFS) of the population was 5 months and the median overall survival (OS) was 10 months. Several factors were predictors of unfavorable survival: age over 75 years, international prognostic index of 2 or higher, refractory disease and de novo DLBCL. The median PFS and OS of the patients who obtained a complete response were 22 months and 40 months, respectively. The most significant toxicities were grade 3-4 hematological toxicities (31% of patients). Given its efficacy and tolerability, R-GemOx can be used in patients ineligible for intensive treatment and serve as a basis for new regimen combinations.

• Authors: Clarisse Cazelles, Karim Belhadj, Hélène Vellemans, Vincent Camus, Elsa Poullot, Philippe Gaulard, Liana Veresezan, Emmanuel Itti, Stéphanie Becker, Muriel Carvalho, Jehan Dupuis, Fabien Le Bras, François Lemonnier, Louise Roulin, Taoufik El Gnaoui, Fabrice Jardin, Nicolas Mounier, Hervé Tilly, Corinne Haioun
• Journal: Leukemia & lymphoma (Leuk Lymphoma) Vol. 62 Issue 9 Pg. 2161-2168 (09 2021) ISSN: 1029-2403 [Electronic] United States
• PMID: 33764240 (Publication Type: Journal Article)

Chemical References

• Oxaliplatin
• Deoxycytidine
• Rituximab
• Gemcitabine

Topics

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Combined Chemotherapy Protocols (adverse effects)
• Deoxycytidine (analogs & derivatives)
• Hematopoietic Stem Cell Transplantation
• Humans
• Lymphoma, Large B-Cell, Diffuse (drug therapy)
• Middle Aged
• Oxaliplatin (therapeutic use)
• Retrospective Studies
• Rituximab (therapeutic use)
• Transplantation, Autologous
• Treatment Outcome
• Young Adult
• Gemcitabine